News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
GlaxoSmithKline Gets FDA Okay for Prostate Combination Drug
June 15, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- GlaxoSmithKline (GSK.L) has won U.S. approval for a fixed-dose combination prostate drug called called Jalyn, combining dutasteride and tamsulosin.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
GlaxoSmithKline
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Spinal muscular atrophy
Biogen Receives Surprise FDA Rejection for High Dose Spinraza
September 24, 2025
·
2 min read
·
Tristan Manalac
Podcast
FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More
September 24, 2025
·
2 min read
·
Heather McKenzie
Spinal muscular atrophy
Much Maligned Manufacturing Site Trips Up Scholar Rock’s Spinal Muscular Atrophy Drug
September 23, 2025
·
2 min read
·
Tristan Manalac
Government
FDA Revives Decades-Dormant Drug as Potential Autism Treatment
September 23, 2025
·
2 min read
·
Tristan Manalac
